Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products

In March 2022, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products.” This document provides detailed recommendations for industry and academic sponsors involved in the development of CAR T cell therapies, aiming to streamline the development process and ensure the safety and efficacy of these innovative treatments.U.S. Food and Drug Administration+5U.S. Food and Drug Administration+5U.S. Food and Drug Administration+5U.S. Food and Drug Administration

Key Highlights:

1. Chemistry, Manufacturing, and Control (CMC):
The guidance emphasizes the importance of robust CMC practices, including:U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

• Vector Manufacturing and Testing: Ensuring the quality and consistency of viral vectors used to modify T cells.
• Cellular Starting Material: Proper collection, handling, and testing of cells to be engineered.U.S. Food and Drug Administration+1U.S. Food and Drug Administration+1
• CAR T Cell Manufacturing and Testing: Establishing control strategies for the manufacturing process, including analytical testing and labeling.
• Managing Manufacturing Changes: Implementing change management and comparability studies during the product lifecycle.
• Manufacturing Sites: Considerations for single-site and multisite manufacturing operations.

2. Nonclinical Recommendations:
The FDA outlines nonclinical considerations, such as:U.S. Food and Drug Administration+1U.S. Food and Drug Administration+1

• CAR Construct and Cellular Component: Evaluating the design and function of the CAR construct and the modified T cells.U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4
• In Vivo Testing: Conducting appropriate animal studies to assess safety and efficacy.
• Additional Modifications: Assessing the impact of any additional genetic modifications to the CAR T cells.U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4

3. Clinical Recommendations:
For clinical development, the guidance provides insights on:U.S. Food and Drug Administration+1U.S. Food and Drug Administration+1

• Study Population: Selecting appropriate patient populations, including considerations for disease stage and pediatric subjects.
• Treatment Plan: Determining dose selection, starting dose, dose escalation strategies, repeat dosing, and staggering of patient enrollment.U.S. Food and Drug Administration+1U.S. Food and Drug Administration+1

Implications for Stakeholders:

This guidance serves as a valuable resource for developers of CAR T cell therapies, offering a structured approach to product development. By adhering to these recommendations, sponsors can facilitate regulatory review processes and contribute to the advancement of safe and effective CAR T cell treatments.U.S. Food and Drug Administration+1U.S. Food and Drug Administration+1

Access the Full Guidance:

The complete guidance document is available here: FDA Guidance Document

Contact Information:

For further inquiries, contact the FDA’s Office of Communication, Outreach and Development (OCOD):

• Phone: 1-800-835-4709 or 240-402-8010
• Email: ocod@fda.hhs.gov